The Hindu Business Line : Lupin plans 3-fold hike in research spend

DRUG company Lupin Ltd has said that there would be a three-fold increase in its research spend - from Rs 40 crore in fiscal 2003-04 to Rs 120 crore in the current fiscal (2004-05).

The Chairman, Dr Desh Bandhu Gupta, said the scale-up in research investments would help accelerate efforts towards the development of new chemical entities, new drug delivery systems and generics research.

At the company's 22 annual general meeting, Dr Gupta said the investments would drive the company's growth in advanced markets. It hopes to file 14 abbreviated new drug applications (ANDAs) this year.

"We have already filed two ANDAs in the first quarter of 2004-05," he said. The company also filed two drug master files, Dr Gupta added.

More Stories on : Research & Development | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lupin plans 3-fold hike in research spend

GSK Pharma India MD to oversee Lanka, Bangladesh

Biocon insulin likely to be in market soon

ICI to invest Rs 800 cr for acquisition, expansion

Apollo moots pvt placement

Standard soon on `employee share-based payments': ICAI

Manu Chhabria's mother stakes claim to estate

M.P. Birla's sisters file caveats

Concept paper for slimmer Companies Act finalised

Hindalco shareholders' no to Lodha & Co

Torrent Pharma, Novartis tie up

HLL looks at `long term'; unfazed by Q2 nos

ITC looks to emerge on top in paper, hotel biz